Immuron Ltd Files October 2025 6-K Report
Ticker: IMRN · Form: 6-K · Filed: Oct 31, 2025 · CIK: 1660046
| Field | Detail |
|---|---|
| Company | Immuron LTD (IMRN) |
| Form Type | 6-K |
| Filed Date | Oct 31, 2025 |
| Risk Level | low |
| Pages | 1 |
| Reading Time | 1 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: sec-filing, 6-K, regulatory-update
Related Tickers: IMRN
TL;DR
Immuron Ltd (IMRN) filed its October 6-K, confirming 20-F filing and foreign private issuer status.
AI Summary
Immuron Limited filed a Form 6-K on October 31, 2025, reporting information for the month of October 2025. The filing indicates the company is a foreign private issuer and will file annual reports under Form 20-F. No specific financial figures or operational updates were detailed in the provided excerpt.
Why It Matters
This filing serves as an update for investors regarding Immuron Ltd's regulatory compliance and reporting status with the SEC for the month of October 2025.
Risk Assessment
Risk Level: low — This filing is a routine administrative report and does not contain material non-public information that would typically impact stock price.
Key Players & Entities
- Immuron Limited (company) — Registrant
- 001-38104 (company) — SEC File Number
- Form 6-K (document) — Filing Type
- Form 20-F (document) — Annual Report Filing
FAQ
What is the purpose of a Form 6-K filing?
A Form 6-K is a report of foreign private issuers that is required to be filed with the SEC when they make public certain information that is made public or required to be made public in their home country.
What is Immuron Limited's SEC file number?
Immuron Limited's SEC file number is 001-38104.
Does Immuron Limited file annual reports under Form 20-F?
Yes, the filing indicates that Immuron Limited files or will file annual reports under cover of Form 20-F.
What period does this 6-K filing cover?
This Form 6-K filing is for the month of October 2025.
Is Immuron Limited furnishing information under Rule 12g3-2(b)?
No, the filing explicitly states 'No' next to the indication for furnishing information pursuant to Rule 12g3-2(b).
Filing Stats: 307 words · 1 min read · ~1 pages · Grade level 18.2 · Accepted 2025-10-30 21:34:21
Filing Documents
- ea0263360-6k_immuron.htm (6-K) — 13KB
- ea026336001ex99-1_immuron.htm (EX-99.1) — 42KB
- ex99-1_001.jpg (GRAPHIC) — 17KB
- ex99-1_002.jpg (GRAPHIC) — 21KB
- ex99-1_003.jpg (GRAPHIC) — 10KB
- 0001213900-25-104358.txt ( ) — 121KB
From the Filing
OF FOREIGN PRIVATE ISSUER UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of October 2025 Commission File Number: 001-38104 IMMURON LIMITED (Name of Registrant) Level 3, 62 Lygon Street, Carlton South, Victoria, 3053, Australia (Address of principal executive office) Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F. Form 20-F Form 40-F Indicate by check mark whether by furnishing the information contained in this Form, the registrant is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934. Yes No If “Yes” is marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b): 82- IMMURON LIMITED EXPLANATORY NOTE Immuron Limited (the “Company”) published one announcement (the “Public Notices”) to the Australian Securities Exchange on October 31, 2025 titled: - Clinical Trial Update - A copy of the Public Notice is attached as an exhibit to this report on Form 6-K. This report on Form 6-K (including the exhibit hereto) shall not be deemed to be “filed” for purposes of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) and shall not be incorporated by reference into any filing under the Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference in such filing. 1 EXHIBITS Exhibit Number Description 99.1 Clinical Trial Update 2 SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. IMMURON LIMITED Date: October 31, 2025 By: /s/ Phillip Hains Phillip Hains Company Secretary 3